EVAXION A/S (EVAX) Stock News

NASDAQ:EVAX - US29970R3030 - ADR

3.25 USD

+0.15 (+4.8%)

Last: 8/22/2025, 8:05:19 PM

3.25 USD

0 (0%)

After Hours: 8/22/2025, 8:05:19 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EVAX Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Evaxion

Evaxion announces business update and second quarter 2025 financial results

9 days ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

10 days ago - By: Benzinga

Insights Ahead: Evaxion Biotech's Quarterly Earnings

12 days ago - By: Evaxion

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

12 days ago - By: Evaxion

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

a month ago - By: Evaxion

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

a month ago - By: Evaxion

Evaxion finalizes agreement with EIB to convert debt into equity

2 months ago - By: Evaxion Biotech

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

2 months ago - By: Evaxion Biotech

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

3 months ago - By: Evaxion Biotech

Evaxion receives grant funding to design new polio vaccine

3 months ago - By: Evaxion Biotech

Evaxion announces business update and first quarter 2025 financial results

3 months ago - By: Evaxion Biotech

Evaxion announces business update and first quarter 2025 financial results

3 months ago - By: Evaxion Biotech

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

3 months ago - By: Evaxion Biotech

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

3 months ago - By: ACCESS Newswire - Mentions: ULY HTCR DGXX LWLG ...

Sidoti Events, LLC's Virtual May Micro-Cap Conference

4 months ago - By: Evaxion Biotech

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

5 months ago - By: Evaxion Biotech

Evaxion to present at World Vaccine Congress

5 months ago - By: Evaxion Biotech

Evaxion announces business update and full year 2024 financial results

5 months ago - By: Evaxion Biotech

Evaxion announces business update and full year 2024 financial results

5 months ago - By: Evaxion Biotech

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

5 months ago - By: Evaxion Biotech

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

6 months ago - By: Evaxion Biotech

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

6 months ago - By: Evaxion Biotech

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

7 months ago - By: Evaxion Biotech

Evaxion announces closing of $10.8 million public offering